NFATC1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL245511	0.61	6/20
SCHEMBL760604	0.60	6/20
SCHEMBL4925138	0.59	6/20
SCHEMBL1009087	0.56	6/20
SCHEMBL1892610	0.56	6/20
SCHEMBL2619228	0.56	6/20
SCHEMBL3147182	0.56	6/20
SCHEMBL3709413	0.55	6/20
SCHEMBL4857118	0.55	6/20
SCHEMBL2268299	0.51	6/20
SCHEMBL2611046	0.51	6/20
Hydrochloric Acid (SCHEMBL3831446)	0.50	6/20
SCHEMBL1004938	0.49	6/20
SCHEMBL3379371	0.48	6/20
SCHEMBL4268142	0.47	6/20
SCHEMBL4268145	0.47	6/20
SCHEMBL3386469	0.46	6/20
SCHEMBL3378612	0.45	6/20
SCHEMBL3382263	0.45	6/20
SCHEMBL6363594	0.44	6/20

Clinical trials — most relevant to NFATC1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Tacrolimus Treatment for Refractory Autoimmune Cytopenia	PHASE4	UNKNOWN
Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction	PHASE4	COMPLETED
Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops	PHASE4	COMPLETED
Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC	PHASE2/PHASE3	NOT_YET_RECRUITING
Cyclosporine For The Treatment Of COVID-19(+)	PHASE2	COMPLETED
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease	PHASE2	COMPLETED
A Study to Test the Effect of Cyclosporine on the Immune System of Patients With Early HIV Disease	PHASE2	COMPLETED
Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC	PHASE2	UNKNOWN
Chidamide Combined With Toripalimab in Sarcoma	PHASE2	COMPLETED
Combined Use of Pulsed Dye Laser and Topical Antiangiogenic Agents for Treatment of Port Wine Stain Birthmarks	PHASE1/PHASE2	WITHDRAWN
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer	PHASE1	COMPLETED
Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors	PHASE1	UNKNOWN
Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC)	EARLY_PHASE1	UNKNOWN
Role of Nox2 in CNI-induced Renal Fibrosis	nan	COMPLETED
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
Feasibility Trial of Preoperative 5-Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma	nan	ACTIVE_NOT_RECRUITING
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient	nan	RECRUITING
The Immunomodulatory Effect of Antrifibrinolytic (Tranexamic Acid) in Total Knee Arthroplasty	nan	UNKNOWN
A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome	nan	COMPLETED
NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients	nan	COMPLETED
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation	nan	COMPLETED
Umbilical Cord Blood Treatment for Refractory Immune Cytopenia	nan	UNKNOWN
The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes	nan	RECRUITING
CD155 Expression in Acute Myeloid Leukemia	nan	COMPLETED
Evaluation of Innovative Combinatorial stratégies of Anti-latency and Anti-immune Activation Drugs Targeting HIV Reservoir	nan	WITHDRAWN
Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients	nan	RECRUITING
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy	nan	COMPLETED
Chi-GVM Regimen for the Treatment of R/R PTCL	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a NFATC1 binder may also engage these)

Protein	Name	Similarity
O77638	—	1.000	O77638 →
Q13469	—	0.997	Q13469 →
P98201	—	0.989	P98201 →
Q60591	—	0.989	Q60591 →
Q3UR85	—	0.988	Q3UR85 →
O88942	—	0.987	O88942 →
P97305	—	0.983	P97305 →
Q9Y2G1	—	0.980	Q9Y2G1 →
P49797	—	0.980	P49797 →
Q12968	—	0.979	Q12968 →
Q8N228	—	0.977	Q8N228 →
A0A0G2JTY4	—	0.977	A0A0G2JTY4 →
O35779	—	0.973	O35779 →
O00287	—	0.973	O00287 →
ELL	RNA polymerase II elongation factor ELL	0.973	landscape →
Q5RAI7	—	0.972	Q5RAI7 →
Q9ERE9	—	0.972	Q9ERE9 →
O14503	—	0.972	O14503 →
Q8VIP2	—	0.972	Q8VIP2 →
P0C6S7	—	0.972	P0C6S7 →
Q9DC04	—	0.971	Q9DC04 →
B3F209	—	0.971	B3F209 →
P22682	—	0.971	P22682 →
CBL	E3 ubiquitin-protein ligase CBL	0.971	landscape →
Q9NP71	—	0.971	Q9NP71 →
Q99PV5	—	0.971	Q99PV5 →
O35780	—	0.971	O35780 →
P04198	—	0.970	P04198 →
Q68FF7	—	0.970	Q68FF7 →
Q63379	—	0.970	Q63379 →